Parkinson’s disease is a progressive, chronic neurological condition that affects movement, cognition, and daily functioning. Research has suggested that mitochondrial dysfunction and impaired cellular energy production may play a role in the disease process.
A study published in the Archives of Neurology (October 2002; Vol. 59, No. 10, pp. 1541–1550) examined the effects of coenzyme Q10 (CoQ10) supplementation in patients with early-stage Parkinson’s disease. CoQ10 is a compound essential for mitochondrial energy production and also functions as an antioxidant, helping protect cells from oxidative damage.
Previous research had shown that CoQ10 levels are reduced in the cells of people with Parkinson’s disease and that cellular energy production is impaired. Animal studies had further suggested that CoQ10 supplementation may help protect the brain regions most affected by the disease.
This clinical study followed 80 patients with early Parkinson’s disease who exhibited classic symptoms, including tremor, muscle stiffness, and slowed movement. Participants were randomly assigned to one of four groups. One group received a placebo containing vitamin E alone, while the other three groups received vitamin E plus CoQ10 at doses of 300 mg/day, 600 mg/day, or 1,200 mg/day. Participants were evaluated one month after starting supplementation and then every four months for a total follow-up period of 16 months.
CoQ10 was well tolerated at all doses. Side effects were mild, and the percentage of participants reporting adverse effects was similar in both the treatment and placebo groups. Patients receiving 300 mg/day and 600 mg/day of CoQ10 experienced less functional decline than those in the placebo group. The group receiving 1,200 mg/day showed the greatest difference, with approximately 44% less decline in motor function, cognitive measures, and the ability to perform activities of daily living compared with placebo.
The researchers also observed that CoQ10 supplementation increased blood levels of CoQ10 and was associated with improved markers of cellular energy production. While this was a relatively small study and does not establish definitive conclusions, it provided early evidence that mitochondrial support may influence disease progression in Parkinson’s disease and helped lay the groundwork for further investigation.
